Genfit and Pierre Fabre, alliance

Lille (France), Cambridge (Mass.), January 7, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111) the biopharmaceutical company at the forefront of research and development of cardiovascular, inflammatory and metabolic drugs today announced a new phase in the evolution of its research collaboration with the PIERRE FABRE Laboratories.

The PIERRE FABRE group and GENFIT have been collaborating on several programs since 2001, and more specifically since 2005 on two drug discovery programs targeting metabolic disorders. The two companies have recently identified a first-in-class group of molecules corresponding to an innovating therapeutic strategy and aiming at a simultaneous effect on Type II diabetes and dyslipidemia and a potential effect on obesity, specifically through a phenotypic approach...
[PDF] GENFIT's Press Release- PDF du Communiqué de Presse GENFIT-

UCB and sanofi-aventis, FDA Approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies

February 19, 2008 - UCB and sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL® (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria. XYZAL® tablets received FDA approval on May 25, 2007 and both formulations are now approved for use in adults and children 6 years and older...Many people suffer from the symptoms associated with common allergic conditions. The immune system of allergy sufferers over-reacts to something in the environment, leading to symptoms that affect their respiratory system, eyes, or skin. Estimates from the American Academy of Allergy, Asthma & Immunology (AAAAI) suggest that indoor and outdoor allergies affect as many as 40 million people in the United States... UCB's press Release- [PDF] sanofi-aventis' Press release- PDF du Communiqué de Presse de sanofi-aventis-

LFB and the French Rare Diseases Alliance, Partnership

Paris, 5 February 2008 - The French pharmaceutical group LFB and the French Rare Diseases Alliance, a collective of 179 associations of patients with rare diseases, signed a two-year agreement. This first agreement serves to confirm and structure relations built between the collective and LFB over nearly five years to ensure transparency and continuity... LFB is a French pharmaceutical group specialised in therapeutic proteins in the form of plasma-derived or biotechnology medicinal products... LFB's Press Release - Communiqué de Presse de LFB-

IPSOGEN, Genomic Grade to improve Breast Cancer diagnosis & treatment decision

Marseille, France, January 28, 2007 – IPSOGEN SAS, a leading molecular diagnostic company based in France and Connecticut, USA announced today the signature of a license agreement with Université Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive rights on the Genomic Grade™...The Genomic Grade™ represents the common core feature of the main breast cancer prognostic genomic signatures published worldwide, as shown by a meta-analysis presented by Pr. Piccart at the St. Gallen Breast Cancer conference in March 2007. Importantly, the Genomic Grade™ can be measured by both DNA microarray and multiplex PCR technologies, as presented at the 2007 meeting of the American Society of Clinical Oncology... [PDF] IPSOGEN's Press Release-

Sanofi Pasteur and Statens Serum Institut , development and marketing of a new vaccine against Tuberculosis

LYON, France, February 14, 2008 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced that it has signed a collaborative research and license agreement with the Statens Serum Institut of Denmark (SSI) for the development and marketing of a new vaccine against tuberculosis (TB), a disease that causes the death of two million people, worldwide, each year... [PDF] Sanofi Pasteur' Press Release - [PDF] Communiqué de Presse de Sanofi Pasteur-

NOVEXEL AND FOREST LABORATORIES, LICENSE AGREEMENT FOR NXL104, A NOVEL BROAD-SPECTRUM BETA LACTAMASE INHIBITOR

Paris, France, 22 January 2008 -- Novexel, the pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, announces that it has entered into an agreement with Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE : FRX), for the development, manufacture and commercialization of Novexel’s novel intravenous beta lactamase inhibitor, NXL104 in combination with Forest’s ceftaroline... Novexel's Press Release - Communiqué de Presse de Novexel-

Trophos, grant from The Michael J. Fox Foundation to evaluate compounds in Parkinson’s disease model

Marseille, February 8th, 2008- Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announces today that The Michael J. Fox Foundation (MJFF) has awarded the company a Therapeutics Development Initiative grant to pursue the evaluation of compounds preventing mitochondrial dysfunction to treat Parkinson’s disease (PD)... Trophos' Press Release - Michael J. Fox Foundation's Press Release-

Servier, Medicinal Chemistry Research Center in Budapest

31 January 2008 - Servier, the leading independent French pharmaceutical group, inaugurated in Budapest a new Medicinal Chemistry Research Center. Staffed by over fifty researchers, this center will be an integral part of the Institut de Recherche Servier (IDRS) and will participate in IDRS research programs, with a particular focus on metabolic diseases and oncology... Servier's Press Release - Communiqué de Presse de Servier-

Faust Pharmaceuticals, Research Agreement with Takeda

Strasbourg, France, January 7, 2008 - Faust Pharmaceuticals S.A., a clinical-stage product company specializing in the discovery and development of drugs for diseases of the nervous system, announced that it has entered into a research agreement with Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company. Under the agreement, Faust will apply its NEUROCLID(TM) platform to identify novel drug candidates that target undisclosed G Protein-Coupled Receptors (GPCRs) of interest to Takeda... Faust Pharmaceuticals' Press Release-

Tornier and Bioset Collaborate on Products for Orthopedic Soft Tissue Repair

February 06, 200 -Tornier, Inc., a global leader in extremities orthopedics, announced that it has entered into an exclusive world-wide technology collaboration in the field of orthopedic soft tissue repair with BioSurface Engineering Technologies, Inc. ("BioSET") to develop, commercialize, and distribute products that will incorporate BioSET’s synthetic growth factor technology. The collaboration will focus initially on ligament and tendon repair products that will feature coatings based on BioSET’s proprietary F2A synthetic growth factor technology (“F2A”)... Tornier's Press Release-

Novagali Pharma, FDA Clearance of IND for US Clinical Trial of Nova63035 in patients with Diabetic Macular Edema

Evry, France, December 19, 2007 – Novagali Pharma, an emerging ophthalmic pharmaceutical company announced that the Company’s Investigational New Drug Application (IND) to conduct a Phase I clinical trial of its Nova63035, an ophthalmic injectable emulsion based on EYEJECT® technology containing a corticosteroid prodrug for the treatment of Diabetic Macular Edema (DME), has been granted by the U.S. Food and Drug Administration (FDA)... Novagali's Press Release - Communiqué de Presse de Novagali-

Ipsen, a Biologics License Application (BLA) for Dysport in cervical dystonia

Paris (France), 31 January 2008 - Ipsen (Euronext: FR0010259150; IPN) announced that the Food and Drug Administration (FDA) has accepted the filing of its BLA for Dysport® in the United States to treat patients with cervical dystonia. This acceptance signifies the start of the review process of the dossier... Ipsen's Press Release -

Cerep, to provide profiling services to support a drug discovery program for Spinal Muscular Atrophy

Paris, France, January 31 , 2008 – Cerep [Eurolist: Cerep] is pleased to announce that it has been selected by Science Applications International Corporation (SAIC) on behalf of the Spinal Muscular Atrophy (SMA) Project through the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health to provide in vitro pharmacological profiling and ADME/Tox services for a multi-year program... english [PDF] Cerep's Press Release - français [PDF] Communiqué de Presse Cerep-